5-甲氧基-1H-苯并[d][1,3]噁嗪-2,4-二酮 | 67765-42-8

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 5-甲氧基-1H-苯并[d][1,3]噁嗪-2,4-二酮
• 中文别名: 5-甲氧基-[1,3]苯并恶嗪-2,4-二酮
• 英文名称: 5-methoxy-1H-benzo-[d][1,3]-oxazine-2,4-dione
• 英文别名: 6-methoxy isatoic anhydride；5-Methoxy-1H-benzo[d][1,3]oxazine-2,4-dione；5-methoxy-1H-3,1-benzoxazine-2,4-dione
• CAS: 67765-42-8
• 化学式: C₉H₇NO₄
• mdl: MFCD11046419
• 分子量: 193.159
• InChiKey: KIZGBTDENGRWRS-UHFFFAOYSA-N

物化性质

• 熔点：
  258-261 °C
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-甲氧基-1H-苯并[d][1,3]噁嗪-2,4-二酮 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 16.0h， 生成 他喹莫德
  参考文献：
  名称：

  Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

  摘要：

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

  DOI：

  10.1021/jm031044w
• 作为产物：
  描述：

  叔-丁基 (3-methoxyphenyl)氨基甲酸酯 在 盐酸 、 叔丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 5-甲氧基-1H-苯并[d][1,3]噁嗪-2,4-二酮
  参考文献：
  名称：

  Studies on nitrogen metabolism using carbon-13 NMR spectroscopy. 6. Biosynthesis of sarubicin A. Synthesis and incorporation of 6-hydroxy[13CO15NH2]anthranilamide

  摘要：

  We have previously demonstrated that 6-hydroxyanthranilic acid (3) is specifically incorporated into sarubicin A (1) by Streptomyces helicus. 6-Hydroxyanthranilamide (4) has now been synthesized in five steps from m-anisidine in a manner that allowed efficient introduction of isotope labels to prepare [(CONH2)-C-13-N-15]-4a. A new synthesis of 3 from m-anisidine has also been developed. 4a was fed to S. helicus, and a 1.29% incorporation into 1b was obtained. Examination of the C-13 NMR spectrum of 1b revealed predominantly intact incorporation, with a minor amount of 4a (0.13%) first undergoing in vivo hydrolysis to the corresponding acid. Thus, carboxamide formation is the next step in the biosynthesis of 1.

  DOI：

  10.1021/jo00023a036

文献信息

• 喹唑啉酮并[2,3-a]咔啉衍生物及其制备方法和应用
  申请人：广西师范大学

  公开号：CN113480537B

  公开（公告）日：2022-05-10

  本发明的主要内容是提供合成一种新的喹唑啉酮并[2,3‑a]咔啉化合物及其制备方法和应用，具有通式（Ⅰ）喹唑啉酮并[2,3‑a]咔啉化合物为，或通式（Ⅱ）的喹唑啉酮并[2,3‑a]咔啉化合物为，并提供了该化合物在制备抗炎药物中的应用。
• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• Pyridazinedione compounds useful in treating neurological disorders
  申请人：Imperial Chemical Industries, PLC

  公开号：US05599814A1

  公开（公告）日：1997-02-04

  The present invention relates to pyridazino[4,5-b]quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]quinolines as active ingredient, and methods for the treatment of neurological disorders.

  本发明涉及吡啶并[4,5-b]喹啉及其药用盐，它们是兴奋性氨基酸拮抗剂，在需要此类拮抗作用时非常有用，例如在治疗神经系统疾病时。该发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的药物组合物，以及治疗神经系统疾病的方法。
• [EN] PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS PYRIDINES
  申请人：ASTRAZENECA AB

  公开号：WO2009153589A1

  公开（公告）日：2009-12-23

  The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

  本发明涉及抑制细胞焦点粘附激酶功能的化合物，其制备方法，含有其作为活性成分的药物组合物，以及它们作为药物的用途，以及用于制造用于治疗温血动物（如人类）癌症等疾病的药物。